Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study

Background/Aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, no large-scale retrospective real-world data are available. This retrospective study aimed to examine the efficacy and safety of pembrolizumab in multiple facilities. Patients and Methods: Data of 167 patients with R/M SCCHN treated with pembrolizumab between December 2019 and February 2022 were analyzed. The endpoint was overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs). OS and PFS were analyzed comparatively with and without irAEs, and complete response (CR) or partial response (PR), and stable disease (SD) or progressive disease (PD) were compared. Results: One hundred thirty-five patients received pembrolizumab alone, whereas the others received pembrolizumab with chemotherapy. For the pembrolizumab only group, the median OS and PFS were 22.7 and 5.1 months, respectively. There were significant differences in OS and PFS between CR or PR and SD or PD (p<0.01, p<0.01, respectively). For pembrolizumab with chemotherapy, the OS was not reached and median PFS was 7.0 months. There was a significant difference in PFS between CR or PR and SD or PD (p<0.01). There was a significant difference in PFS between patients with and without irAEs (p=0.02). Conclusion: The real-world therapeutic effect of pembrolizumab for R/M SCCHN was comparable to that observed in the KEYNOTE048 trial. In addition, irAEs and best overall response were considered as prognostic factors.

[1]  F. Clatot,et al.  Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. , 2021, European journal of cancer.

[2]  K. Tsukahara,et al.  Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma , 2021, In Vivo.

[3]  M. Ono,et al.  Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer , 2021, In Vivo.

[4]  D. Ettinger,et al.  Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. , 2020, JAMA oncology.

[5]  Hideaki Takahashi,et al.  Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma , 2020, AntiCancer Research.

[6]  P. Dennis,et al.  Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis , 2020, Clinical pharmacology and therapeutics.

[7]  D. Schadendorf,et al.  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.

[8]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[9]  F. Bidault,et al.  Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2019, European journal of cancer.

[10]  C. Fushimi,et al.  Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study , 2019, Acta oto-laryngologica.

[11]  A. Costantini,et al.  Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[13]  J. Lee,et al.  Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. , 2017, Lung cancer.

[14]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[15]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[16]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[17]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[18]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[19]  R. Stupp,et al.  A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).